BRIGHTCOVE (BCOV)

US10921T1016 - Common Stock

4.37  +0.01 (+0.23%)

After market: 4.39 +0.02 (+0.46%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BCOV. BCOV was compared to 83 industry peers in the IT Services industry. BCOV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BCOV is valued expensive at the moment.



3

1. Profitability

1.1 Basic Checks

In the past year BCOV was profitable.
BCOV had a positive operating cash flow in the past year.
In the past 5 years BCOV reported 4 times negative net income.
In the past 5 years BCOV always reported a positive cash flow from operatings.

1.2 Ratios

BCOV has a Return On Assets (-4.34%) which is comparable to the rest of the industry.
BCOV has a Return On Equity of -9.58%. This is comparable to the rest of the industry: BCOV outperforms 43.21% of its industry peers.
Industry RankSector Rank
ROA -4.34%
ROE -9.58%
ROIC N/A
ROA(3y)-4.02%
ROA(5y)-5.56%
ROE(3y)-9.19%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BCOV's Gross Margin of 61.60% is amongst the best of the industry. BCOV outperforms 81.48% of its industry peers.
In the last couple of years the Gross Margin of BCOV has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BCOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.06%
GM growth 5Y0.65%

4

2. Health

2.1 Basic Checks

BCOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCOV has more shares outstanding
Compared to 5 years ago, BCOV has more shares outstanding
BCOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BCOV has an Altman-Z score of 0.06. This is a bad value and indicates that BCOV is not financially healthy and even has some risk of bankruptcy.
BCOV has a worse Altman-Z score (0.06) than 81.48% of its industry peers.
There is no outstanding debt for BCOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.06
ROIC/WACCN/A
WACC11.39%

2.3 Liquidity

BCOV has a Current Ratio of 0.75. This is a bad value and indicates that BCOV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BCOV (0.75) is worse than 86.42% of its industry peers.
BCOV has a Quick Ratio of 0.75. This is a bad value and indicates that BCOV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.75, BCOV is not doing good in the industry: 86.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75

4

3. Growth

3.1 Past

BCOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 145.45%, which is quite impressive.
BCOV shows a decrease in Revenue. In the last year, the revenue decreased by -0.22%.
The Revenue has been growing slightly by 4.07% on average over the past years.
EPS 1Y (TTM)145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y0.64%
Revenue growth 5Y4.07%
Sales Q2Q%-2.02%

3.2 Future

Based on estimates for the next years, BCOV will show a very strong growth in Earnings Per Share. The EPS will grow by 64.74% on average per year.
The Revenue is expected to grow by 0.01% on average over the next years.
EPS Next Y100%
EPS Next 2Y64.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.51%
Revenue Next 2Y0.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 87.40, the valuation of BCOV can be described as expensive.
BCOV's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 27.40. BCOV is valued rather expensively when compared to this.
BCOV is valuated quite expensively with a Price/Forward Earnings ratio of 122.41.
The rest of the industry has a similar Price/Forward Earnings ratio as BCOV.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.67, BCOV is valued quite expensively.
Industry RankSector Rank
PE 87.4
Fwd PE 122.41

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BCOV is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as BCOV.
Industry RankSector Rank
P/FCF 51.03
EV/EBITDA 23.25

4.3 Compensation for Growth

BCOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BCOV's earnings are expected to grow with 64.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.87
PEG (5Y)N/A
EPS Next 2Y64.74%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BCOV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BRIGHTCOVE

NASDAQ:BCOV (1/6/2025, 7:17:53 PM)

After market: 4.39 +0.02 (+0.46%)

4.37

+0.01 (+0.23%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners70.58%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change-2.63%
Market Cap197.44M
Analysts45.71
Price Target4.54 (3.89%)
Short Float %0.47%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)56.43%
Max EPS beat(2)143.57%
EPS beat(4)4
Avg EPS beat(4)114.38%
Min EPS beat(4)56.43%
Max EPS beat(4)161.44%
EPS beat(8)6
Avg EPS beat(8)77.66%
EPS beat(12)10
Avg EPS beat(12)100.79%
EPS beat(16)14
Avg EPS beat(16)114.38%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.56%
Max Revenue beat(2)0.87%
Revenue beat(4)2
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.87%
Revenue beat(8)2
Avg Revenue beat(8)-1%
Revenue beat(12)6
Avg Revenue beat(12)-0.14%
Revenue beat(16)10
Avg Revenue beat(16)0.35%
PT rev (1m)4.71%
PT rev (3m)14.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)N/A
EPS NY rev (3m)100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 87.4
Fwd PE 122.41
P/S 0.99
P/FCF 51.03
P/OCF 14.47
P/B 2.07
P/tB 11.63
EV/EBITDA 23.25
EPS(TTM)0.05
EY1.14%
EPS(NY)0.04
Fwd EY0.82%
FCF(TTM)0.09
FCFY1.96%
OCF(TTM)0.3
OCFY6.91%
SpS4.42
BVpS2.11
TBVpS0.38
PEG (NY)0.87
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.34%
ROE -9.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.6%
FCFM 1.94%
ROA(3y)-4.02%
ROA(5y)-5.56%
ROE(3y)-9.19%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.06%
GM growth 5Y0.65%
F-Score7
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 50.16%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion 186.6%
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z 0.06
F-Score7
WACC11.39%
ROIC/WACCN/A
Cap/Depr(3y)143.44%
Cap/Depr(5y)123.4%
Cap/Sales(3y)7.87%
Cap/Sales(5y)6.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y100%
EPS Next 2Y64.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y0.64%
Revenue growth 5Y4.07%
Sales Q2Q%-2.02%
Revenue Next Year-1.51%
Revenue Next 2Y0.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year979.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.43%
OCF growth 3Y-40.43%
OCF growth 5Y12.05%